PHS
TARS icon

PFM Health Sciences’s Tarsus Pharmaceuticals TARS Stock Holding History

PFM Health Sciences’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.55M Sell
40,579
-39,647
-49% -$2.53M 0.22% 85
2026
Q1 		$5.63M Buy
80,226
+52,888
+193% +$3.7M 0.51% 61
2025
Q4 		$2.24M Buy
+27,338
New +$2.04M 0.22% 68

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PFM Health Sciences's TARS Position: Q2 2026 in Review

PFM Health Sciences reduced its Tarsus Pharmaceuticals (TARS) stake by 49% in Q2 2026, selling an estimated $2.53M and leaving 40,579 shares worth $2.55M. The position accounts for 0.22% of the portfolio, ranked #85.

PFM Health Sciences first reported a position in TARS in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.63M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • PFM Health Sciences held 40,579 shares of Tarsus Pharmaceuticals worth $2.55M as of Q2 2026.
  • PFM Health Sciences sold 39,647 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.53M.
  • Tarsus Pharmaceuticals made up 0.22% of PFM Health Sciences's portfolio in Q2 2026, its #85 holding.
  • PFM Health Sciences first reported a position in Tarsus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PFM Health Sciences's Tarsus Pharmaceuticals position peaked at $5.63M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.